- Home
- TMQ vs BBNX Comparison
TMQ vs BBNX Comparison
Compare TMQ & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | BBNX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Canada | United States |
| Employees | N/A | 423 |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.8M | 493.1M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TMQ | BBNX |
|---|---|---|
| Price | $3.25 | $16.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | ★ 1.7M | 996.1K |
| Earning Date | 04-02-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $8.80 |
| 52 Week High | $11.29 | $32.71 |
Technical Indicators
Market Signals| Indicator | TMQ | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 64.22 |
| Support Level | $2.00 | $16.02 |
| Resistance Level | $3.66 | $32.52 |
| Average True Range (ATR) | 0.19 | 1.03 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 27.01 | 83.96 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.